Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EDIT | US
0.16
4.97%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.38
3.30
3.48
3.25
Editas Medicine Inc. a clinical stage genome editing company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101 which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301 a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover develop and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine Inc. was incorporated in 2013 and is based in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
49.3%1 month
50.7%3 months
65.7%6 months
66.0%-
-
1.24
0.17
0.10
-1.36
0.70
-
-207.21M
278.77M
278.77M
-
-14.02K
-
-82.20
-61.23
12.65
29.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.71
Range1M
0.94
Range3M
2.87
Rel. volume
1.45
Price X volume
10.39M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
Kamada Ltd | KMDA | Biotechnology | 5.2 | 298.89M | -0.57% | 20.04 | 3.41% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.36 | 0.76 | Cheaper |
Ent. to Revenue | 0.70 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.24 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 65.70 | 74.67 | Par |
Debt to Equity | 0.17 | -1.82 | Expensive |
Debt to Assets | 0.10 | 0.26 | Cheaper |
Market Cap | 278.77M | 3.73B | Emerging |